Daratumumab combined with dexamethasone and lenalidomide or bortezomib in relapsed/refractory multiple myeloma (RRMM) patients: Report from the multiple myeloma GIMEMA Lazio group

Francesca Fazio, Luca Franceschini, Valeria Tomarchio, Angela Rago, Maria Grazia Garzia, Luca Cupelli, Velia Bongarzoni, Alessandro Andriani, Svitlana Gumenyuk, Agostino Tafuri, Agostina Siniscalchi, Alfonso Piciocchi, Paolo De Fabritiis, Luca De Rosa, Tommaso Caravita di Toritto, Ombretta Annibali, Maria Cantonetti, Maria Teresa Petrucci

Open source

DOI: 10.1002/jha2.359
Published: 2022-01-15
Container: eJHaem
Publisher: Wiley
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1002/jha2.359,
  title = {Daratumumab combined with dexamethasone and lenalidomide or bortezomib in relapsed/refractory multiple myeloma (RRMM) patients: Report from the multiple myeloma GIMEMA Lazio group},
  author = {Francesca Fazio and Luca Franceschini and Valeria Tomarchio and Angela Rago and Maria Grazia Garzia and Luca Cupelli and Velia Bongarzoni and Alessandro Andriani and Svitlana Gumenyuk and Agostino Tafuri and Agostina Siniscalchi and Alfonso Piciocchi and Paolo De Fabritiis and Luca De Rosa and Tommaso Caravita di Toritto and Ombretta Annibali and Maria Cantonetti and Maria Teresa Petrucci},
  year = {2022},
  journal = {eJHaem},
  doi = {10.1002/jha2.359},
  url = {https://doi.org/10.1002/jha2.359}
}

RIS

TY  - JOUR
TI  - Daratumumab combined with dexamethasone and lenalidomide or bortezomib in relapsed/refractory multiple myeloma (RRMM) patients: Report from the multiple myeloma GIMEMA Lazio group
AU  - Francesca Fazio
AU  - Luca Franceschini
AU  - Valeria Tomarchio
AU  - Angela Rago
AU  - Maria Grazia Garzia
AU  - Luca Cupelli
AU  - Velia Bongarzoni
AU  - Alessandro Andriani
AU  - Svitlana Gumenyuk
AU  - Agostino Tafuri
AU  - Agostina Siniscalchi
AU  - Alfonso Piciocchi
AU  - Paolo De Fabritiis
AU  - Luca De Rosa
AU  - Tommaso Caravita di Toritto
AU  - Ombretta Annibali
AU  - Maria Cantonetti
AU  - Maria Teresa Petrucci
PY  - 2022
JO  - eJHaem
DO  - 10.1002/jha2.359
UR  - https://doi.org/10.1002/jha2.359
ER  -

APA

Fazio, F., Franceschini, L., Tomarchio, V., Rago, A., Garzia, M. G., Cupelli, L., Bongarzoni, V., Andriani, A., Gumenyuk, S., Tafuri, A., Siniscalchi, A., Piciocchi, A., Fabritiis, P. D., Rosa, L. D., Toritto, T. C. D., Annibali, O., Cantonetti, M., & Petrucci, M. T. (2022). Daratumumab combined with dexamethasone and lenalidomide or bortezomib in relapsed/refractory multiple myeloma (RRMM) patients: Report from the multiple myeloma GIMEMA Lazio group. eJHaem. https://doi.org/10.1002/jha2.359

Source records

crossref · retrieved 2026-09-27T03:56:12.043Z